Regenesance, a Ventac Partners portfolio company, receives a seed-stage investment from Life Sciences Fund Amsterdam of USD 900,000.
We participate in numerous events promoting our portfolio companies and meeting our clients.
Regenesance B.V., a Ventac Partners portfolio company, opens Boston office to assist with drug development strategy in USA.
Mikael Oerum is appointed as Chairman of Neuroscience Technologies L.S.P and Neuroscience Technology Limited, a Spanish and UK based biomedical company with expertise in human pain neurophysiology contract research organization, see www.nsc-tec.com.
The Norwegian University of Science and Technology (NTNU) secures seed funding for APIM Therapeutics with the support of Ventac Partners.
Avexxin, a Ventac Partners portfolio company, closes Series A financing round of USD 2.8 million enabling the company to take its lead compound forward through clinical trial phase I/IIa.